Objective To compare the therapeutic efficacy of surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in the treatment of patients with moderate to severe aortic valve stenosis. Methods A retrospective analysis was conducted on the clinical data of 120 patients with moderate to severe aortic valve stenosis. The patients who underwent TAVR were classified as the TAVR group, while those who underwent SAVR were classified as the SAVR group, with 60 cases in each group. The two groups were compared in terms of operative duration, intraoperative blood loss, postoperative hospital stay, postoperative ICU stay, as well as perivalvular leakage, atrioventricular block, common postoperative complications such as poor incision healing and pulmonary infection. Echocardiography was used to measure the left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular fractional shortening (LVFS), left ventricular ejection fraction (LVEF), and peak aortic valve velocity (Vmax) in both groups before surgery, at 1 week postoperatively, 6 months postoperatively, and 1 year postoperatively. Results The operative duration, postoperative hospital stay and postoperative ICU stay in the TAVR group were shorter, and intraoperative blood loss was less than those in the SAVR group (P<0.05). LVEDD, LVESD, IVST, LVPWT and Vmax decreased while LVEF and LVFS increased at each postoperative time point in both groups compared with preoperative values (P<0.05). However, IVST and LVPWT in the TAVR group were higher than those in the SAVR group at 1 week, 6 months and 1 year after surgery (P<0.05). The incidence of paravalvular leak in the TAVR group was higher than that in the SAVR group (P<0.05). There was no statistically significant difference in the incidence of other complications between the two groups (P>0.05). Conclusion Both TAVR and SAVR achieve favorable efficacy in the treatment of patients with moderate to severe aortic valve stenosis, of which TAVR results in less surgical trauma and faster postoperative recovery. For elderly patients with poor baseline status or multiple comorbidities, TAVR may be the preferred option. However, SAVR is recommended for patients with specific anatomical features such as bicuspid aortic valve. Clinically, appropriate treatment regimens should be selected individually according to the patient's condition.